Anrotinib is a common anti-vascular targeted therapy drug, there is no so-called “three major contraindications”, the common contraindications of Anrotinib include allergy to Anrotinib, patients with bleeding risk, pregnant or lactating women, patients with severe hepatic or renal insufficiency, and so on. 1. Allergic to Anrotinib: Anrotinib is not recommended for patients who are allergic to the components of Anrotinib. 2. patients with bleeding risk: while killing malignant tumor cells, Anrotinib will also cause damage to normal tissues, so if there is hemoptysis in patients or patients with central lung squamous carcinoma, taking this drug will increase the risk of bleeding, and it is usually not recommended to take it. 3. Pregnant women: taking Anrotinib may increase the probability of thromboembolism to some extent. The use of amlotinib in pregnant or lactating women may result in serious adverse reactions to the fetus or newborn, and is not recommended. 4. Patients with severe hepatic insufficiency: If the patient has severe hepatic insufficiency, prolonged use of Amrotinib may aggravate the degree of liver function damage, and generally not recommended to take Amrotinib. The use of drugs should be standardized under the guidance of a doctor, do not blindly use drugs, so as not to delay the condition or cause adverse reactions.